Antibacterial Agents TRIZ Cases

C-terminal heavy chain deletion plus a heterologous sequence enables efficient production of high-quality immunoglobulin multimers.

Modified IFN-γ fused to targeting moieties lowers off-target toxicity while preserving therapeutic activity at tumor or immune cells.

Cyanoimidazole compounds deliver rapid activity against Malassezia and Staphylococcus while sparing normal skin flora in non-human animals.

Dual-wavelength photodynamic therapy uses a photosensitizer to treat Staphylococcus aureus skin infections without antibiotics, heating, or allergy risk.

Closed-loop plasma NO generation uses sensors, a controller, and split gas flows to keep medical nitric oxide delivery precise and safe.

A cross-linked amphiphilic hydrogel binds antimicrobial agents to kill bacteria, absorb exudate, and support haemostasis without leaching.

Novel lantibiotics and recombinant producer bacteria target VRE colonization and infection where conventional antibiotics lose effectiveness.

Chimeric cell wall hydrolases pair selective S. aureus binding with enzymatic lysis to spare commensal bacteria in skin infection treatment.

Separate dried glucosinolate and myrosinase components stay stable in storage, then release antimicrobial isothiocyanates when water is added.

Pre-coated sutures release dermal fillers gradually in skin to avoid bolus bulges and achieve precise, homogeneous augmentation.

Modified Cholix fusion molecules carry biologic cargo across gut epithelium to improve oral bioavailability, liver delivery, and dosing convenience.

INR-guided thrombomodulin dosing helps target septic patients with coagulopathy, improving outcomes while limiting unnecessary anticoagulant use.

Poorly absorbed oxadiazoles stay concentrated in the gut to inhibit C. difficile vegetative cells, spores, and toxin production.

Amidine-substituted monobactams help counter β-lactamase-driven resistance while retaining antibacterial activity against multidrug-resistant Gram-negative bacteria.

A lactobacillus and lactoferrin composition inhibits GBS growth early, offering pregnancy-related prevention and treatment without antibiotics.

A virulence-deficient Pseudomonas vaccine shifts immunity toward protein antigens, enabling longer-lasting protection across O5 and O1 serotypes.

Combining isomaltulose with 1-kestose or lactulose helps boost beneficial urogenital bacteria while suppressing harmful microbes.

Novel heterocyclic compounds inhibit resistant gram-negative bacteria by targeting LpxC-related pathways, supporting treatment of UTIs and other infections.

Fusaricidin compounds from Paenibacillus or Bacillus target drug-resistant pathogens while improving antimicrobial efficacy with lower toxicity risk.

Detecting heteroresistance in purified bacterial cultures helps avoid monotherapy failure and select effective antibiotic combinations.

Targets AgrA-regulated virulence in S. aureus with triazoloquinazolinone derivatives that suppress quorum sensing without driving resistance.

XTEN-linked GLP-2 resists rapid degradation, extends half-life and bioavailability, and reduces dosing frequency for gastrointestinal therapy.

ApoA-1 fused to a dimerizing domain extends circulation time, lowers immunogenicity, and preserves cholesterol efflux activity.

Modified 2-aminobenzimidazole compounds disperse Salmonella biofilms and inhibit regrowth to treat persistent gallbladder infections in carriers.

Specific antimicrobials are paired with DispersinB to avoid enzyme inactivation, disperse PNAG biofilms, and kill embedded bacteria.

Aqueous buffer, sucrose, and surfactant balance high anti-PD-L1 antibody concentration with stability and retained biological activity.

Multispecific ISV polypeptides bind CD3 and tumor antigens to drive MHC-independent T cell killing with better stability and manufacturability.

Novel depsipeptides target drug-resistant microbes with broad-spectrum activity, favorable bioavailability, and low toxicity.

Using Lon protease and related agents, this case shows an indirect route to lower c-MYC when direct targeting fails due to undruggability.

Engineered peptide linkers enable intestinal protease-triggered polypeptide release while limiting steric hindrance and preserving oral stability.

Targeted tetracycline substitutions broaden antibacterial activity and help address resistance while preserving therapeutic effectiveness.

Controlled disulfide-forming peptide linkers stabilize multispecific Fab antibodies, prevent homodimers, and extend in vivo half-life.

New 13-series resolvins from n-3 DPA boost phagocytosis and regulate inflammasomes to clear infection without immunosuppression.

A hydrate crystal form replaces amorphous valnemulin hydrochloride to improve stability, resist moisture uptake, and ease pharmaceutical formulation.

Thiol-reactive linker chemistry helps ADCs stay stable in circulation while releasing cytotoxic payloads in target cells to reduce off-target toxicity.

Targeting class A, B, and D β-lactamases, these boronic acid derivatives preserve β-lactam antibiotic activity against resistant bacteria.

Beneficial bacteria such as R. gnavus and L. reuteri boost host antimicrobial peptides to suppress resistant infections without driving antibiotic resistance.

Encapsulated levofloxacin and doxycycline in biphasic vesicles improve intracellular targeting while reducing side effects from multi-antibiotic therapy.

Oxygen radical irradiation converts tryptophan solution into FKYN, KYN, and bactericidal radicals, cutting synthesis time and cost.

Novel ring-fused 2-pyridone compounds boost existing antibiotics against MRSA and E. faecalis while lowering resistance risk.

CHAP-Sh3b chimeric polypeptides selectively lyse S. aureus and S. hominis while sparing S. epidermidis to preserve skin microbiome balance.

Novel darobactin compounds treat Gram-negative and polymyxin-resistant infections while reducing nephrotoxicity and side effects.

New Formula I heterocyclic compounds target gram-positive and gram-negative resistant bacteria to sustain antibacterial activity where existing antibiotics fail.

Covalent bicyclic peptide-oligonucleotide conjugates improve DNA/RNA affinity, lower toxicity, and support more controllable tissue distribution.

Encapsulating therapeutics in recombinant Spirulina protects them from digestive and respiratory degradation while enabling stable, lower-cost non-parenteral delivery.

Covalent small-molecule USP7 inhibitors use tailored substituents and linkages to improve potency, selectivity, solubility, and toxicity.

A dual-binding antibody neutralizes TNFα and IL-17A to address anti-TNF non-response while improving stability and treatment durability.

Controlled water activity and acidic pH let fractionated Manuka honey inhibit biofilms and pathogens without fermentation.

Directly screens donor-derived vaginal strains in vivo to find bacteria that engraft, persist, and improve dysbiosis more reliably than in vitro selection.

Self-assembling UPEC peptide nanofibers deliver multiple epitopes sublingually to build lasting UTI protection without disrupting the gut microbiome.

Reducing culture temperature to 32°C resolves the trade-off between migratory activity and IL-12p70 yield in dendritic cell generation.

Ester-modified relebactam prodrugs enable oral administration, resolving the contradiction between intravenous efficacy and ease of treatment.

Phosphonate polymers suppress microbial virulence factor expression without destroying beneficial bacteria, avoiding antibiotic resistance concerns.

Spirolactam CGRP antagonists improve microsomal stability by modifying residues R1 and R2, extending half-life.

7-substituted 2-benzylamino-6-oxopurine compounds inhibit Clostridium difficile growth.

Cationic oil-in-water emulsions protect unmodified RNA from nuclease degradation while avoiding cytotoxic effects associated with chemical modifications.

Introducing a sulfonamide structure at the N-1 position of the uracil ring achieves potent human dUTPase inhibitory activity for antitumor drug development.

Segmenting high-dose tablets into coated mini-units improves swallowability and masks bitter tastes without delaying dissolution.

A dry powder inhalation composition combines an aminoglycoside antibiotic with a biofilm-modifying macrolide to achieve high pulmonary deposition.

TP3 and TP4 peptides destroy MRSA bacteria through membrane disruption while avoiding antibiotic resistance development.

Segmented isoquinoline derivatives target specific enzyme pockets to resolve the trade-off between therapeutic efficacy and kinase selectivity.

Targeted amino acid substitutions at residues A15-A20 in ghrelin analogs increase biological potency by improving GHS receptor binding efficiency.

Synthesized pleuromutilin derivatives feature specific phenyl ring substitutions that enhance antimicrobial activity against bacterial pathogens.

Conjugating pharmacophores to phospholipid analogs resolves stability and immunostimulatory effectiveness trade-offs.

Formula I compounds target Clostridium perfringens while preserving gut flora health, resolving broad-spectrum collateral damage.

Triazolopyridine carboxamide derivatives block monoacylglycerol lipase to raise endogenous lipid levels, addressing the lack of effective therapeutic options.

Mannose-modified dextran carriers target CD206 expressing cells, resolving the trade-off between broad tissue distribution and specific macrophage uptake.

Metal-retaining filtration separates metallic contaminants from methylene blue, achieving pharmaceutical purity levels above 97%.

Glycine prevents Maillard reaction coloration while sucralose provides sweetness without glycemic response or gastrointestinal issues.

Multivalent phenolic hydroxyl carboxylic acid selenium complex salts derived from lignin hydrolysis.

Pyrazole derivatives inhibit human SGLT1 transporters to block intestinal glucose absorption.

A recombinant BCG bacterium expressing a dominant negative SOCS1 mutant to enhance cytokine production.

Combining a nicotinic acetylcholine receptor ligand with an alpha4beta2 positive allosteric modulator enhances analgesic activity.

Novel arginine-phenylalanine peptides disrupt bacterial membranes through electrostatic attraction and amphiphilic insertion.

Calcium-independent dipicolylamine derivatives bind external phosphatidylserine, avoiding scramblase activation and normal cell targeting.

Hydrazino-imidazoquinolines link to antigens via hydrazone bonds, preserving protein stability while enabling cytokine biosynthesis.

Conjugating STa toxin with modified carrier proteins overcomes poor immunogenicity to generate protective antibody titers.

Polyvinylpyrrolidone enables oral delivery of live attenuated Mannheimia haemolytica bacteria for ruminants.

Novel heterocyclic substituted piperazines inhibit CXCR3 receptor activity to treat inflammatory and autoimmune diseases.

Zinc-lysine complex blocks sweat pores via precipitation, avoiding skin irritation from acidic aluminum salts.

Indole compounds accumulate in mitochondria to scavenge reactive oxygen species, preventing oxidative stress and ischemic reperfusion injury.

Amide bond modification enables rapid photodegradation of quinolone antibiotics, eliminating environmental persistence and resistance risks.

Segmented test compositions using species-specific polypeptides eliminate cross-reactivity between Anaplasma infections.

A recombinant avipoxvirus vector expresses BTV VP2 and VP5 polypeptides to induce a robust immune response in susceptible animals.

A carbapenem binds the allosteric site of penicillin-binding protein 2a to trigger active site opening for bacterial inactivation.

Cross-linking monomeric lysins into dimers reduces plasma clearance and extends stability to treat Streptococcus infections.

Localized glycerol monolaurate application on tampon covers inhibits TSST-1 production while maintaining low foaming and extractable levels.

Novel Lawsonia intracellularis bacterium strain enables production of specific monoclonal antibodies for targeted immunization and detection.

Segmenting antigen and adjuvant into separate polymersomes resolves membrane protein instability while boosting CD8+ T cell immunity.

Substituted tetrazolyl sulfonamide compounds bind zinc metalloenzymes to prevent β-lactam ring hydrolysis and treat resistant infections.

Ceftolozane and tazobactam achieve high epithelial lining fluid concentrations, overcoming poor bronchial diffusion in nosocomial pneumonia.

A combination immunogenic composition uses segmented aqueous and lipid phases to protect against avian coryza, encephalomyelitis, and fowl pox.

Segmented M. tuberculosis antigens bypass slow culture methods by inducing specific T-cell responses that eliminate false positives from vaccinated individuals.

Pyridinium hydrogen sulfate catalyzes a one-pot reaction to produce the compound, eliminating volatile organic solvent emissions.

A naringin and sepiolite feed additive regulates microbial fermentation in ruminants.

Synthesizing 2-alkoxy[4,3:6,3-terpyridine]-3-carbonitrile compounds via multi-component reactions to generate new pyridine derivatives.